|
|||||
|
|
Healthcare utilization and costs associated with dabigatran compared to warfarin treatment in newly diagnosed patients with non-valvular atrial fibrillation |
|
| Authors: | Kevin Francis Chen Yu Hasmik Alvrtsyan Stephen Sander Sabyasachi Ghosh Yajing Rao |
| Affiliation: | 1. Trinity Partners, Waltham, MA, USA;2. Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA |
| Abstract: | |
| Keywords: | Atrial fibrillation Costs Dabigatran Warfarin |